靶向EphB4受体分子探针的研究进展

doi:10.3760/cma.j.issn.1673-422X.2016.11.010

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (11): 841-844.doi: 10.3760/cma.j.issn.1673-422X.2016.11.010

靶向EphB4受体分子探针的研究进展

解清华，朱华，刘菲，韩雪迪，夏传琴，杨志

100142 北京大学肿瘤医院暨北京市肿瘤防治研究所核医学科恶性肿瘤发病机制及转化研究所教育部重点实验室（解清华、朱华、刘菲、韩雪迪、杨志）；四川大学化学学院（解清华、夏传琴）

收稿日期:2016-03-17 出版日期:2016-11-08 发布日期:2016-11-02
通讯作者: 杨志，Email: pekyz@163.com E-mail:pekyz@163.com
基金资助:
国家自然科学基金（81371592、81401467、81571705、81501519）；北京市自然科学基金（7154188）

Advance of molecular imaging probes targeted for EphB4 receptor

Xie Qinghua, Zhu Hua, Liu Fei, Han Xuedi, Xia Chuanqin, Yang Zhi

Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Beijing 100142, China; College of Chemistry, Sichuan University, Chengdu 610041, China

Received:2016-03-17 Online:2016-11-08 Published:2016-11-02
Contact: Yang Zhi E-mail:pekyz@163.com
Supported by:
National Natural Science Foundation of China (81371592, 81401467, 81571705, 81501519); Beijing Municipal Natural Science Foundation of China (7154188)

摘要/Abstract

摘要： 促红细胞生成素产生肝细胞受体（Eph）B型受体4与肿瘤生长和肿瘤血管形成密切相关，并且在许多肿瘤中过量表达。EphB4靶向探针可提高肿瘤诊断的准确性和特异性。大量针对该靶点的分子探针已经被设计出来，有望为肿瘤的早期诊断和治疗提供新的方法。

关键词: 受体, EphB4, 肿瘤, 核医学, 分子探针

Abstract: The erythropoietinproducing hepatocellular receptor (Eph) B4 receptor is closely associated with tumor growth and angiogenesis, which is overexpressed in a wide variety of tumors. Molecular probes targeted for EphB4 receptor can improve the accuracy and specificity of tumor diagnosis. A lot of molecular probes targeted for EphB4 receptor have been designed, which are expected to provide new means for the early diagnosis and therapeutics of tumors.

Key words: Receptor, EphB4, Neoplasms, Nuclear medicine, Molecular probes

解清华，朱华，刘菲，韩雪迪，夏传琴，杨志. 靶向EphB4受体分子探针的研究进展[J]. 国际肿瘤学杂志, 2016, 43(11): 841-844.

Xie Qinghua, Zhu Hua, Liu Fei, Han Xuedi, Xia Chuanqin, Yang Zhi. Advance of molecular imaging probes targeted for EphB4 receptor[J]. Journal of International Oncology, 2016, 43(11): 841-844.

参考文献

［1］ Mosch B, Reissenweber B, Neuber C, et al. Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis［J］. J Oncol, 2010, 2010: 135285. DOI: 10.1155/2010/135285. ［2］ Huang G, Li M. The role of EphB4 and IGFIR expression in breast cancer cells［J］. Int J Clin Exp Pathol, 2015, 8(5): 59976004. ［3］ Ferguson BD, Liu R, Rolle CE, et al. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target［J］. PLoS One, 2013, 8(7): e67668. DOI: 10.1371/journal.pone.0067668. ［4］ Hasina R, Mollberg N, Kawada I, et al. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers［J］. Cancer Res, 2013, 73(1): 184-194. DOI: 10.1158/00085472.CAN120915. ［5］ Chen T, Liu X, Yi S, et al. EphB4 is overexpressed in gliomas and promotes the growth of glioma cells［J］. Tumor Biol, 2013, 34(1): 379-385. DOI: 10.1007/s13277-012-0560-7. ［6］ Tu Y, He S, Fu J, et al. Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients［J］. Clin Transl Oncol, 2012, 14(3): 214220. DOI: 10.1007/s1209401207862. ［7］ Li M, Zhao ZW, Zhang Y, et al. Overexpression of Ephb4 is associated with carcinogenesis of gastric cancer［J］. Dig Dis Sci, 2011, 56(3): 698-706. DOI: 10.1007/s10620-010-1346-7. ［8］ Li M, Zhao Z. Clinical implications of EphB4 receptor expression in pancreatic cancer［J］. Mol Biol Rep, 2013, 40(2): 1735-1741. DOI: 10.1007/s1103301222245. ［9］ Liu R, Ferguson BD, Zhou Y, et al. EphB4 as a therapeutic target in mesothelioma［J］. BMC Cancer, 2013, 13: 269. DOI: 10.1186/1471-2407-13-269. ［10］ Lisle JE, MertensWalker I, Rutkowski R, et al. Eph receptors and their ligands: promising molecular biomarkers and therapeutic targets in prostate cancer［J］. Biochim Biophys Acta, 2013, 1835(2): 243-257. DOI: 10.1016/j.bbcan.2013.01.003. ［11］ Xi H Q, Wu XS, Wei B, et al. Eph receptors and ephrins as targets for cancer therapy［J］. J Cell Mol Med, 2012, 16(12): 2894-2909. DOI: 10.1111/j.15824934.2012.01612.x. ［12］ Barquilla A, Pasquale EB. Eph receptors and ephrins: therapeutic opportunities［J］. Annu Rev Pharmacol Toxicol, 2015, 55: 465-487. DOI: 10.1146/annurevpharmtox-011112-140226. ［13］ GuijarroMuoz I, Sánchez A, MartínezMartínez E, et al. Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab［J］. Med Oncol, 2013, 30(2): 572. DOI: 10.1007/s12032-013-0572-1. ［14］ Xiong C, Huang M, Zhang R, et al. In vivo smallanimal PET/CT of EphB4 receptors using 64Culabeled peptide［J］. J Nucl Med, 2011, 52(2): 241-248. DOI: 10.2967/jnumed.110.081943. ［15］ Huang M, Xiong C, Lu W, et al. Dualmodality micropositron emission tomography/computed tomography and nearinfrared fluorescence imaging of EphB4 in orthotopic glioblastoma xenograft models［J］. Mol Imaging Biol, 2014, 16(1): 74-84. DOI: 10.1007/s11307-013-0674-3. ［16］ Zhang R, Xiong C, Huang M, et al. Peptideconjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts［J］. Biomaterials, 2011, 32(25): 5872-5879. DOI: 10.1016/j.biomaterials.2011.04.070. ［17］ Noberini R, Mitra S, Salvucci O, et al. PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity［J］. PLoS One, 2011, 6(12): e28611. DOI: 10.1371/journal.pone.0028611. ［18］ Chen FY, Yan JJ, Yi HX, et al. TNYL peptide functional chitosangstearate conjugate micelles for tumor specific targeting［J］. Int J Nanomedicine, 2014, 9: 4597-4608. DOI: 10.2147/IJN.S69572. ［19］ Wang Z, Sun J, Qiu Y, et al. Specific photothermal therapy to the tumors with high EphB4 receptor expression［J］. Biomaterials, 2015, 68: 32-41. DOI: 10.1016/j.biomaterials.2015.07.058. ［20］ You J, Zhang R, Xiong C, et al. Effective photothermal chemotherapy using doxorubicinloaded gold nanospheres that target EphB4 receptors in tumors［J］. Cancer Res, 2012, 72(18): 4777-4786. DOI: 10.1158/00085472.CAN-12-1003. ［21］ Xiong CY, Cao QZ, Li C. PET/CT imaging of EphB4 receptors in melanoma xenograft with a 68Galabeled cyclic TNYLRAW peptide［J］. J Nucl Med, 2013, 54 (Suppl-2): 1042. ［22］ Kaur S, Venktaraman G, Jain M, et al. Recent trends in antibodybased oncologic imaging［J］. Cancer Lett, 2012, 315(2): 97-111. DOI: 10.1016/j.canlet.2011.10.017. ［23］ Krasnoperov V, Kumar SR, Ley E, et al. Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth［J］. Am J Pathol, 2010, 176(4): 2029-2038. DOI: 10.2353/ajpath.2010.090755. ［24］ Liu S, Li D, Park R, et al. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Culabeled hAb47 and hAb131 antibodies［J］. J Nucl Med, 2013, 54(7): 1094-1100. DOI: 10.2967/jnumed.112.116822. ［25］ Li D, Liu S, Liu R, et al. Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring［J］. Mol Pharm, 2013, 10(1): 329-336. DOI: 10.1021/mp300461b. ［26］ Li D, Liu S, Liu R, et al. EphB4targeted imaging with antibody h131, h131F(ab′)2 and h131Fab［J］. Mol Pharm, 2013, 10(12): 4527-4533. DOI: 10.1021/mp400354y. ［27］ Mamat C, Mosch B, Neuber C, et al. Fluorine18 radiolabeling and radiopharmacological characterization of a benzodioxolylpyrimidinebased radiotracer targeting the receptor tyrosine kinase EphB4［J］. Chem Med Chem, 2012, 7(11): 1991-2003. DOI: 10.1002/cmdc.201200264. ［28］ Ebert K, Wiemer J, Caballero J, et al. Development of indazolylpyrimidine derivatives as highaffine EphB4 receptor ligands and potential PET radiotracers［J］. Bioorg Med Chem, 2015, 23(17): 6025-6035. DOI: 10.1016/j.bmc.2015.06.040.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

靶向EphB4受体分子探针的研究进展

Advance of molecular imaging probes targeted for EphB4 receptor

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价